LENZ Therapeutics’ (LENZ) “Buy” Rating Reiterated at HC Wainwright

HC Wainwright restated their buy rating on shares of LENZ Therapeutics (NASDAQ:LENZ) in a research report report published on Thursday,Benzinga reports. The brokerage currently has a $38.00 price target on the stock.

Several other equities research analysts also recently commented on LENZ. Raymond James assumed coverage on LENZ Therapeutics in a report on Friday, September 27th. They set an “outperform” rating and a $37.00 target price for the company. William Blair upgraded LENZ Therapeutics to a “strong-buy” rating in a report on Friday, August 30th. Finally, Piper Sandler reaffirmed an “overweight” rating and issued a $36.00 price target on shares of LENZ Therapeutics in a research report on Thursday, August 15th. Six equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Buy” and a consensus price target of $35.40.

LENZ Therapeutics Stock Up 7.8 %

Shares of NASDAQ:LENZ opened at $35.07 on Thursday. The firm has a 50-day simple moving average of $24.94 and a 200 day simple moving average of $21.24. LENZ Therapeutics has a fifty-two week low of $14.07 and a fifty-two week high of $37.13.

LENZ Therapeutics (NASDAQ:LENZ) last posted its earnings results on Wednesday, November 6th. The company reported ($0.38) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.47) by $0.09. During the same period in the prior year, the firm earned ($1.33) earnings per share. As a group, analysts expect that LENZ Therapeutics will post -3.15 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of LENZ. American International Group Inc. bought a new position in shares of LENZ Therapeutics during the first quarter worth approximately $44,000. SG Americas Securities LLC bought a new stake in shares of LENZ Therapeutics during the third quarter worth about $107,000. GSA Capital Partners LLP acquired a new position in LENZ Therapeutics in the 3rd quarter valued at approximately $246,000. Squarepoint Ops LLC acquired a new stake in LENZ Therapeutics in the second quarter valued at $181,000. Finally, BNP Paribas Financial Markets bought a new position in shares of LENZ Therapeutics during the first quarter worth about $362,000. 54.32% of the stock is currently owned by institutional investors.

LENZ Therapeutics Company Profile

LENZ Therapeutics, Inc, a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.